ESMO 2018 | Limiting duration of treatment with checkpoint inhibitors: the data

Jeffrey Weber

Jeffrey Weber, MD, PhD, of the Perlmutter Cancer Center, New York, NY, discusses the latest clinical trials and explores the comparative efficacy of single agent and combination therapy for melanoma involving checkpoint inhibitors. Dr Weber concludes the interview, indicating the application of a Positron Emission Tomography (PET) scan in patients 1-2 years into checkpoint inhibitor therapy, to determine the safety of the treatment. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video